欧盟GMP附录15确认与验证修订版英文中文.docx

1、欧盟GMP附录15确认与验证修订版英文中文EUROPEAN COMMISSIONENTERPRISEDIRECTORATE-GENERALSingle market, regulatory environment, industries under vertical legislationPharmaceuticals and cosmeticsBrussels,30 March 2015EudraLex欧盟药品管理法Volume 4EU Guidelines forGood Manufacturing Practice forMedicinal Products for Human and

2、Veterinary Use第四卷欧盟人用和兽用药品GMP指南Annex 15: Qualification and validation附录15:确认和验证Legal basis for publishing the detailed guidelines:Article 47 of Directive 2001/83/EC on the Community code relating to medicinal products for human use and Article 51 of Directive 2001/82/EC on the Community code relatin

3、g to veterinary medicinal products. This document provides guidance for the interpretation of the principles and guidelines of good manufacturing practice (GMP) for medicinal products as laid down in Directive 2003/94/EC for medicinal products for human use and Directive 91/412/EEC for veterinary us

4、e.发布该细化指南的法律依据:人用药物欧共体法案指令2001/83/EC第47章和兽用药物欧共体法案指令2001/82/EC第51章。本文件为人药GMP指令2003/94/EC以及兽药GMP指令91/412/EEC的原则和指南提供诠释。Status of the document: Revision文件状态：修订版Reasons for changes:Since Annex 15 was published in 2001 the manufacturing and regulatory environment has changed significantly and an update

5、is required to this Annex to reflect this changed environment. This revision to Annex 15 takes into account changes to other sections of the EudraLex, Volume 4, Part I, relationship to Part II, Annex 11, ICH Q8, Q9, Q10 and Q11, QWP guidance on process validation, and changes in manufacturing techno

6、logy.变更原因：从2001年附录15发布以后，制药生产和法规环境都有了显著变化，需要相应的更新来反映变化的环境。本文对附录15所做的修订考虑了欧盟法规第四卷第一部分质量管理和第二部分活性物质作起始物料以及附录11计算机化系统的验证、ICH Q8药物研发、ICH Q9质量风向管理、ICH Q11药物研发和生产、质量工作组的工艺验证指南和生产技术的变化。Deadline for coming into operation:1 October 2015最终实施日期：2015年10月1日原则 2概述 31. 确认和验证的组织和计划 32. 文件，包括验证主计划 53. 设备、设施、公用工程和系统的

7、确认阶段 75. 工艺验证 106. 运输确认 197. 包装验证 208. 公用工程的确认 209. 检验方法验证 2110. 清洁验证 2111. 变更控制 2512. 词汇表 26PrincipleThis Annex describes the principles of qualification and validation which are applicable to the facilities, equipment, utilities and processes used for the manufacture of medicinal products and may

8、also be used as supplementary optional guidance for active substances without introduction of additional requirements to EudraLex, Volume 4, Part II. It is a GMP requirement that manufacturers control the critical aspects of their particular operations through qualification and validation over the l

9、ife cycle of the product and process. Any planned changes to the facilities, equipment, utilities and processes, which may affect the quality of the product, should be formally documented and the impact on the validated status or control strategy assessed. Computerised systems used for the manufactu

10、re of medicinal products should also be validated according to the requirements of Annex 11. The relevant concepts and guidance presented in ICH Q8, Q9, Q10 and Q11 should also be taken into account.原则本附录描述了确认与验证的基本原则，适用于药品生产中的设施、设备、公用系统及工艺,也可以用于第四卷第二部分活性物质作起始物料的附加要求中没有介绍部分的补充性、选择性指南。GMP要求生产商应通过确认和验

11、证对整个生命周期内的产品和工艺涉及的关键操作中的关键因素来进行控制。所有影响产品质量的计划性变更（含设施、设备、工艺系统和工艺），都应当有正式文件或记录，并评估其对验证状态或是控制策略的影响。用于药品生产的计算机化系统也应根据附录11的要求进行验证。同时，应当考虑现行的ICH Q8、Q9、Q10、Q11中的相关理念和指南要求。GeneralA quality risk management approach should be applied throughout the lifecycle of a medicinal product. As part of a quality risk m

12、anagement system, decisions on the scope and extent of qualification and validation should be based on a justified and documented risk assessment of the facilities, equipment, utilities and processes. Retrospective validation is no longer considered an acceptable approach. Data supporting qualificat

13、ion and/or validation studies which were obtained from sources outside of the manufacturers own programmes may be used provided that this approach has been justified and that there is adequate assurance that controls were in place throughout the acquisition of such data.概述质量风险管理的方法应作为质量风险管理系统的一部分贯穿于

14、药品的整个生命周期，应基于对设施、设备、公用系统和工艺的论证和书面风险评估决定确认和验证的范围和程度。回顾性验证不再被认为是可接受的方式。如果方法经过论证，并且获取数据的整个过程中有足够的保证性控制措施，也可以使用从生产商自身程序以外获得的用于支持确认和/或验证研究的数据。1. ORGANISING AND PLANNING FOR QUALIFICATION AND validATION1. 确认和验证的组织和计划1.1.All qualification and validation activities should be planned and take the life cycle

15、of facilities, equipment, utilities, process and product into consideration.1.1. 所有的确认和验证都应当被计划，并考虑到设施、设备、公用系统、工艺和产品的生命周期。1.2.Qualification and validation activities should only be performed by suitably trained personnel who follow approved procedures.1.2. 确认和验证活动应只能由经过培训合格的人员严格按照批准的程序实施。1.3.Qualifi

16、cation/validation personnel should report as defined in the pharmaceutical quality system although this may not necessarily be to a quality management or a quality assurance function. However, there should be appropriate quality oversight over the whole validation life cycle.1.3. 确认或验证人员应按照药品质量体系中指定

17、要求进行报告，尽管并不一定是报告给质量管理或质量保证部门。然而，对于整个验证生命周期来说，应当有合适的质量监督。1.4.The key elements of the site qualification and validation programme should be clearly defined and documented in a validation master plan (VMP) or equivalent document.1.4. 应当在验证主计划（VMP）或其等同文件中，清晰地界定和记录现场确认与验证程序的关键性要素。1.5. The VMP or equivale

18、nt document should define the qualification/validation system and include or reference information on at least the following:1.5. 验证主计划或其等同文件中应定义确认/验证体系，至少包括如下信息：i. Qualification and validation policy;i. 确认与验证的方针政策。ii. The organisational structure including roles and responsibilities for qualificati

19、on and validation activities;ii. 在确认和验证活动中的组织结构，包括分工和职责。iii.Summary of the facilities, equipment, systems, processes on site and the qualification and validation status;iii. 现场设施、设备、系统、工艺汇总表及其确认和验证状态。iv.Change control and deviation management for qualification and validation;iv. 确认与验证活动的变更控制和偏差管理。v.

20、 Guidance on developing acceptance criteria;v. 开发可接受标准的指南。vi.References to existing documents;vi. 现有文件的参考资料。vii.The qualification and validation strategy, including requalification, where applicable.vii. 确认与验证的策略，适当时应包括再确认。1.6.For large and complex projects, planning takes on added importance and se

21、parate validation plans may enhance clarity1.6. 对于大型和复杂的项目，增加计划重点和独立的验证计划将有助于明晰要做的工作。1.7.A quality risk management approach should be used for qualification and validation activities. In light of increased knowledge and understanding from any changes during the project phase or during commercial pro

22、duction, the risk assessments should be repeated, as required. The way in which risk assessments are used to support qualification and validation activities should be clearly documented.1.7. 在确认与验证活动中应使用质量风险管理的方法，随着在项目开展或者商业化生产的过程中的知识积累及理解加深，应当根据需要对风险进行不断地重复评估，并清楚地记录确认与验证的风险评估所采用的方法。1.8. Appropriate

23、 checks should be incorporated into qualification and validation work to ensure the integrity of all data obtained.1.8. 应将适当的检查加入到确认和验证工作中，以保证所获得的数据的完整性。2. DOCUMENTATION, INCLUDING VMP2. 文件，包括验证主计划2.1. Good documentation practices are important to support knowledge management throughout the product

24、lifecycle.2.1. 在产品的生命周期中，良好的文件管理对于知识管理而言是非常重要的。2.2. All documents generated during qualification and validation should be approved and authorised by appropriate personnel as defined in the pharmaceutical quality system.2.2. 确认与验证产生的所有文件都应当由药品质量管理体系规定的人批准和授权。2.3. The inter-relationship between docume

25、nts in complex validation projects should be clearly defined.2.3. 在复杂的验证项目中，应清楚地说明文件之间的内在关系。2.4. validation protocols should be prepared which defines the critical systems, attributes and parameters and the associated acceptance criteria.2.4. 制定验证方案的时候，应当定义关键系统、属性、参数及相关的可接受标准。2.5. Qualification docu

26、ments may be combined together, where appropriate, e.g. installation qualification (IQ) and operational qualification (OQ).2.5. 确认文件适当的时候可以合并，例如IQ和OQ的文件可以合并在一起。2.6. Where validation protocols and other documentation are supplied by a third party providing validation services, appropriate personnel a

27、t the manufacturing site should confirm suitability and compliance with internal procedures before approval. Vendor protocols may be supplemented by additional documentation/test protocols before use.2.6. 如果验证方案和其它文件记录由验证服务第三方提供，应当由企业内部的合适人员确认其适用性，满足内部规定后方可批准。在使用之前，可由附加的文件或测试对供应商提供的方案进行补充。2.7. Any s

28、ignificant changes to the approved protocol during execution, e.g. acceptance criteria, operating parameters etc., should be documented as a deviation and be scientifically justified.2.7. 在执行期间，对已批准方案的任何重大变更，如可接受标准、操作参数等，均需按照偏差记录在册，并进行科学合理的评判。2.8. Results which fail to meet the pre-defined acceptanc

29、e criteria should be recorded as a deviation and be fully investigated according to local procedures. Any implications for the validation should be discussed in the report。2.8. 若验证结果不符合预定的可接受标准需作为偏差处理，并按照内部规程进行全面调查。任何与偏差关联的东西都应当在验证报告中进行讨论。2.9. The review and conclusions of the validation should be r

30、eported and the results obtained summarised against the acceptance criteria. Any subsequent changes to acceptance criteria should be scientifically justified and a final recommendation made as to the outcome of the validation.2.9. 验证的评价和结论都应当被报告，且结果应与可接受标准比对，对可接受标准的任何后期变更都应当进行科学的评判，并在验证结果中做出最终建议。2.1

31、0. A formal release for the next stage in the qualification and validation process should be authorised by the relevant responsible personnel either as part of the validation report approval or as a separate summary document. Conditional approval to proceed to the next qualification stage can be giv

32、en where certain acceptance criteria or deviations have not been fully addressed and there is a documented assessment that there is no significant impact on the next activity.2.10. 由相关的负责人对确认与验证过程中的阶段性放行，既可以作为验证报告批准的一部分，也可以是单独的总结文件。因某个可接受标准未达到或偏差未关闭，并通过评估确定对下一阶段活动无显著影响，可以有条件的放行进入下一阶段。3. QUALIFICATION STAGES FOR EQUIPMENT, FACILITIES, UTILITIES AND SYSTEMS.3. 设备、设施、公用工程和系统的确认阶段3.1. Qualification activities should co